1. New Strategies to Prevent CV Events After Hospital Discharge

2. Program Agenda

3. Crisis and Unmet Needs in Medically Ill Hospitalized Patients

4. Call to Action

5. World Thrombosis Day Facts

6. Absolute Risk of DVT in Hospitalized Patients

7. Lack of Prophylaxis in Medical Patients

8. Cochrane Review of Interventions for Implementation of Hospital VTE Thromboprophylaxis

9. Trials of VTE Prophylaxis in Hospitalized Medical Patients

10. 3 Randomized Trials

11. VTE After Hospital Discharge

12. Risk of VTE Extends Post-Hospital Discharge

13. More Than Half of VTE Occurs After 10 Days of Prophylaxis

14. Extended VTE Prophylaxis: 3 Failed Trials Medical Patients

15. ADOPT and MAGELLAN Lessons Learned

16. MARINER Trial Rivaroxaban

17. Summary

18. Prevention of VTE, Stroke, and Rehospitalization for Medically Ill Hospitalized Patients

19. Fatal Saddle PE Autopsy

20. Brigham and Women's Hospital Readmission With NEW VTE Within 30 Days of Hospital Discharge

21. VTE After Hospital Discharge

22. Prevention

23. Betrixaban

24. APEX Study Design

25. Study Design Key Inclusion Criteria

26. Baseline Characteristics Primary Admission Diagnoses

27. Primary Efficacy Endpoint

28. Symptomatic VTE Events

29. Primary Safety Endpoint Major Bleeding

30. Percent Fatal Bleeding and ICH Safety Population

31. FDA: Betrixaban Indication and Use

32. Rate of Stroke or TIA

33. VTE-Related Rehospitalization

34. Primary Efficacy Outcome by History of VTE

35. Summary of Betrixaban

36. Summary Betrixaban Substudies

37. Management of Major Bleeding Among Patients Taking DOACs: State-of-the-Art

38. What Is Major Bleeding?

39. Measures to Treat Significant Bleeding Short of Reversal

40. Reversal Agents

41. Idarucizumab Is BIG

42. Idarucizumab Full Cohort

43. Novel Mechanism of Action Provides Rapid Reversal of Factor Xa Inhibitor Activity Without Prohemostatic or Anticoagulant Effects

44. Andexanet: FDA Approved

45. Time Courses of Anti-Factor Xa Activity Before and After the Administration of Andexanet in Healthy Volunteers: 2016

46. Bleeding Patients 2018: Clinical Hemostatic Efficacy

47. 30-Day Assessment in Clinical Trial of Patients who Bled

48. Summary

49. Abbreviations

50. Abbreviations (cont)